1)Swerdlow SH, Campo E, Harris NL, et al:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2008
2)横田浩充,吉川直之,矢冨裕,他:造血器腫瘍核酸増幅同定検査の標準化に向けたRT-PCR法分析誤差要因の検討 Major bcr/ablキメラmRNAの検出を例として.日臨検自動化会誌 29:21-26,2004
3)糸賀栄,横田浩充,南木融,他:模擬標準物質を用いたMajor BCR-ABLキメラ遺伝子定量検査の施設間差是正への試み.日臨検自動化会誌 34:275-283,2009
4)van Dongen JJ, Macintyre EA, Gabert JA, et al:Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13:1901-1928,1999
5)Hughes TP, Kaeda J, Branford S, et al:Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432,2003
6)Gabert J, Beillard E, van der Velden VH, et al:Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17:2318-2357,2003
7)Hughes T, Deininger M, Hochhaus A, et al:Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37,2006
8)White HE, Matejtschuk P, Rigsby P, et al:Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 116:e111-e117,2010
9)日本血液学会(編):造血器腫瘍診療ガイドライン 2018年版補訂版(http://www.jshem.or.jp/gui-hemali/index.html)(最終アクセス:2021年6月22日)
10)糸賀栄:白血病関連遺伝子検査の外部精度評価の試み.医療検査と自動化 45:503-512,2020